Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Celldex Therapeutics, Inc. logoCelldex Therapeutics, Inc.

CLDX · Nasdaq · USD · Market cap $2.2B · 198 employees

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic antibodies for patients with severe inflammatory, allergic, autoimmune, and other diseases.

FAIL · Does not pass the screen
27.42 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price27.42 USD at the 20 Nov 2026 close
  • Fair valueUnder review: our model's value is 2.36x the price, above our 2.00x limit.
  • Our regime readDistribution, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 3.48)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: range not available (screen dated 2026-11-20).

Current read
Distribution ?
Screened · screened 2026-11-20
  • Trend Distribution
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 3.48, read 2026-11-19
  • Ethical does not pass the values gate
Price27.42 USD
Fair valueUnder review
Ethical score70.0/100
Our investment reviews on this name
2026-11-19Read Distribution27.55-0.5% to today ✓Markup gives way to Distribution after a 9% slide in 7 days
2026-11-12Read Markup30.15-9.1% to today Markdown gives way to Markup
2026-10-28Read Markdown29.37-6.6% to today ✓Distribution gives way to Markdown after a 22% slide in 4 weeks
2026-10-02Read Distribution37.89-27.6% to today ✓Accumulation gives way to Distribution after a 9% slide in 5 weeks

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its distribution label.

Celldex Therapeutics, Inc. holds its Distribution at $27.42. Consolidating, no directional conviction, held for 66 days.

As held on the ledger · 2026-11-20
PhaseDistribution · caution
Quantitative stateConsolidating, no directional conviction, held for 66 days
Price at the screen$27.42
ValuationN/A trailing · -6.66 forward price to earnings
Values screenFAIL · score 70.0
Beta1.03
The Workings

Five Screens: CLDX's Results

FAIL. Interest-bearing securities

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 0.40% Below 33% Pass
Interest-bearing cash 84.00% Below 33% Fail
Receivables 5.30% Below 49% Pass

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Celldex Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 84% of its assets, well over the ~33% line, so it does not pass on the financial screens.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when CLDX's ethical verdict changes

Today CLDX does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Fair value under review. Our model's value is 2.36x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.

Method.

The Street's Range
29.00Street low 66.00Street average 100.00Street high 27.42Price

Street: 14 covering, consensus Strong Buy. Average target +141%.

Chart
The Business, in Plain Words

Antibody developer flashes fair value gap yet no opportunity

Picture a lab racing to craft monoclonal antibodies against severe autoimmune conditions. Celldex sits there with a stated fair value well above the share price, yet the opportunity rating stays none. Revenue has collapsed 98 percent, profit margins remain zero and return on equity is negative 49 percent, so the numbers give no reason to engage.

The ethical screen clears but that is not enough. Forward earnings sit at negative 7.9 times with an unknown moat and fifteen analysts offering no consensus rating. The gap to the median target of 54 dollars looks tempting on paper alone, yet the underlying business shows nothing that would change our stance.

Biotech pipelines carry binary risk and heavy cash burn. Without profits or revenue growth the firm may need repeated funding rounds that dilute holders further. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-6.7x
EPS, trailing-4.29
EPS, forward-4.21
Profit margin0.0%currently unprofitable
Return on equity-49.5%not currently earning a positive return on equity
FCF yield-7.01%
Debt to equity1.52a meaningful debt load worth watching
Current ratio10.97comfortably covers its short-term bills
Beta1.03moves a little more than the market
Short interest, float0.15%
52-week range22.33 - 45.14
Market cap$2.2B
Employees198

CLDX-specific watchpoints · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Distribution $27.96 +1.5% Entry 16
2026-11-19 Distribution · changed $27.55 -8.6% Entry 15

The framework has shifted from markup to distribution since the last review.

2026-11-12 Markup · changed $30.15 +0.7% Entry 14

The framework has shifted from markdown to markup since the last review.

2026-11-05 Markdown $29.93 +0.7% Entry 13
2026-11-04 Markdown $29.71 -1.3% Entry 12
2026-11-03 Markdown $30.10 +0.0% Entry 11
2026-11-02 Markdown $30.10 +2.5% Entry 10

Earnings landed in this window.

2026-10-28 Markdown · changed $29.37 +1.5% Entry 9

The framework has shifted from distribution to markdown since the last review.

2026-10-21 Distribution $28.93 -3.2% Entry 8
2026-10-14 Distribution $29.89 -21.1% Entry 7

Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on CLDX

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in CLDX's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $32.28 -8.6% · $914 -8.6%
2 months $32.24 -8.5% · $915 -8.5%
3 months $29.88 -1.3% · $987 -1.3%
6 months $27.94 +5.6% · $1,056 +5.6%
1 year $20.92 +41.0% · $1,410 +41.0%
2 years $34.64 -14.8% · $852 -14.8%
3 years $34.80 -15.2% · $848 -15.2%
5 years $31.04 -5.0% · $950 -5.0%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever CLDX does next, these words stay.

Celldex Therapeutics, Inc. · CLDX · Distribution · $27.42
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.